In a report released today, Laura Sutcliffe from Citi maintained a Hold rating on Ansell, with a price target of A$39.50.
According to TipRanks, Sutcliffe is a 3-star analyst with an average return of 1.3% and a 50.29% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh.
In addition to Citi, Ansell also received a Hold from Morgan Stanley’s David Bailey in a report issued on August 31. However, on August 25, Jefferies maintained a Buy rating on Ansell (Other OTC: ANSLF).
Based on Ansell’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of A$1.1 billion and a net profit of A$118.09 million. In comparison, last year the company earned a revenue of A$1.02 billion and had a net profit of A$48.3 million
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANSLF in relation to earlier this year.
